Clinical Trial

Mitoxantrone Hydrochloride Liposome, Cytarabine, G-CSF Plus Venetoclax vs. Azacitidine Plus Venetoclax for MDS-IB2 and Secondary/Elderly AML

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study aims to evaluate the efficacy and safety of mitoxantrone hydrochloride liposome, subcutaneous cytarabine and G-CSF combined with venetoclax (CMG+Ven) versus azacitidine combined with venetoclax (VA) in the treatment of adult myelodysplastic syndrome IB2 (MDS-IB2) and newly diagnosed secondary or elderly AML.
Trial Details
NCT Number NCT07735117
Lead Sponsor Ruijin Hospital
Collaborators: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Conditions Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
Enrollment 168 participants
Start Date 2026-07-30
Primary Completion 2028-07-20 (estimated)
Study Completion 2029-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-29